Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Sunday, Johnson & Johnson Notes 45% Overall Response Rate, 7.2-Month Median Duration Of Response, And 6.8-Month Progression-Free Survival With Subcutaneous Amivantamab In Metastatic Head And Neck Cancer

Author: Benzinga Newsdesk | October 20, 2025 02:18am

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients

New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors

Posted In: JNJ


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist